Figure 3. PLX4720 antitumor activity is host CCR2 dependent.

(A) Groups of 5 WT, Ccl2^–/–, or Ccr2^–/– mice were inoculated with 5 × 10⁵ SM1WT1 cells. Mice received vehicle or PLX4720 (20 mg/kg i.p.) daily from day 3 to 10 after tumor inoculation. (B and C) Groups of 5 WT or Ccl2^–/– mice were inoculated with 5 × 10⁵ SM1WT1 cells. Mice received vehicle or PLX4720 (20 mg/kg i.p.) daily from day 3 to 10 after tumor inoculation. Some groups of mice additionally received cIg or anti-CCL2 mAb (20 μg i.p.) on days 2, 3, 10, 17, and 24. Tumor sizes are represented as the mean ± SEM. Statistical differences in tumor sizes between mice treated with vehicle or PLX4720 therapy were determined by a Mann-Whitney test (*P < 0.05). (A–C) Data are representative of 2 independent experiments.